Integral Derivatives’s AstraZeneca AZN Stock Holding History

Integral Derivatives’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,750	Closed	-$254K	–	1124
2017 Q3	$254K	Sell	3,750 -41,000	-92%	-$2.59M	﹤0.01%	945
2017 Q2	$3.05M	Buy	+44,750	New	+$2.92M	0.06%	207
2017 Q1	–	Sell	-3,950	Closed	-$216K	–	1158
2016 Q4	$216K	Buy	3,950 +350	+10%	+$19.9K	﹤0.01%	983
2016 Q3	$237K	Hold	3,600	–	–	0.01%	853
2016 Q2	$217K	Hold	3,600	–	–	0.01%	824
2016 Q1	$203K	Buy	+3,600	New	+$216K	0.01%	744
2015 Q3	–	Sell	-4,400	Closed	-$280K	–	1090
2015 Q2	$280K	Hold	4,400	–	–	0.01%	892
2015 Q1	$301K	Sell	4,400 -35,100	-89%	-$2.44M	0.01%	825
2014 Q4	$2.78M	Sell	39,500 -20,000	-34%	-$1.43M	0.05%	324
2014 Q3	$4.25M	Sell	59,500 -27,100	-31%	-$1.98M	0.08%	229
2014 Q2	$6.43M	Buy	+86,600	New	+$6.26M	0.11%	135

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Integral Derivatives's AZN Position: Q1 2017 in Review

Integral Derivatives sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 4,548 shares — an estimated $265K sold.

Integral Derivatives first reported a position in AZN in Q4 2013 and held it in 5 quarters. The position peaked at $1.77M in Q2 2014. 460 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Integral Derivatives reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 4,548 AstraZeneca shares in Q1 2017, an estimated $265K.
Integral Derivatives first reported a position in AstraZeneca in Q4 2013 and held it in 5 quarters.
Integral Derivatives's AstraZeneca position peaked at $1.77M in Q2 2014.
460 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.